Doctor accused of sexual abuse by multiple colleagues identified as prominent cardiologist

The name and employer of a doctor accused of sexually and physically abusing multiple women is no longer being kept from the public. After an official revoked a non-publication order, it was revealed that the doctor in question is Rajeev Kumar Pathak, MBBS, PhD, of Canberra Heart Rhythm in Canberra, Australia.  

Region Canberra provided a full report of the incident, noting that Pathak faces 20 charges in total, including six counts of assault, two counts of sexual intercourse without consent and a separate count of attempted sexual intercourse without consent. He has entered a plea of not guilty for every charge. 

Pathak was arrested in January, but his identity was kept from the public. He was refused bail at the time, but granted bail weeks later. 

The decision to lift the non-publication order came after the magistrate overseeing the case learned that at least three of the five alleged victims said they would support such an action. Pathak’s lawyers argued that his name needed to be withheld from the public so that he could still communicate with his patients. However, he has been suspended from practicing medicine as the case continues to unfold.

Region Canberra went over the different accusations in detail, summarizing the full history of the case and where it stands today. 

Click the link below for the full story: 

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.

The imaging manufacturer expects to spend between $227 million and $340 million on tariff mitigation efforts, leaders said Wednesday.